Sai Life Sciences Q1 FY26 PAT up 22% YoY, revenue rises 13%

Results View source PDF Explain this filing

SAILIFE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-4.1%Reaction day

₹1414.00

prior close

₹1375.00

announcement price

After-mkt

timing

Nifty Smallcap 250market-0.0%-4.1% vs market

Pharmaceuticals peers, median of 167sector+0.3%-4.4% vs sector

On the reaction day the stock moved 4.1 pts less than Nifty Smallcap 250 and 4.4 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.0

10m

-0.0

15m

+0.1

30m

+0.6

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-4.1-0.0-4.1+0.3-4.4

Next day

+1.1-0.1+1.1+0.7+0.4

+2.3+0.1+2.2+0.6+1.8

+3.5-0.1+3.6+0.2+3.3

+2.8+0.0+2.8+1.2+1.6

+2.4-0.4+2.8+0.2+2.2

+2.1-0.1+2.1+0.2+1.9

15d

+5.0+0.7+4.2+0.8+4.1

+12.4+0.7+11.8+2.4+10.0

+10.0-2.4+12.4+1.6+8.5

—————

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 167Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Sai Life Sciences reported Q1 FY26 standalone revenue of Rs 5,467 million, up 13.2% YoY from Rs 4,830 million. Standalone PAT grew 22.2% to Rs 713 million from Rs 584 million. Consolidated revenue rose 11.7% to Rs 5,543 million, PAT up 21.2% to Rs 733 million. EPS basic Rs 3.36 standalone, Rs 3.46 consolidated. Deloitte auditors issued an unmodified review. No new exceptional items this quarter.

Likely market impact

Strong YoY profit growth on steady revenue gains. Clean unmodified auditor review. No new exceptional items this quarter.